Aleksandra Rizo
Director/Board Member at SYNDAX PHARMACEUTICALS, INC.
Net worth: - $ as of 30/04/2024
Profile
Aleksandra Rizo is currently the President & Chief Executive Officer at Vividion Therapeutics, Inc. and a Director at Syndax Pharmaceuticals, Inc. She previously worked as an Executive Director-Strategy & Clinical Leader at Celgene Corp.
from 2018 to 2019, a Senior Director & Team Leader Compound Development at Janssen Research & Development LLC from 2008 to 2018, and as the Chief Medical Officer & Executive Vice President at Geron Corp.
from 2019 to 2022.
Rizo holds a doctorate degree from the University of Groningen, the University of Tokyo, and Saints Cyril & Methodius University of Skopje.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 15/05/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Aleksandra Rizo active positions
| Companies | Position | Start |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Director/Board Member | 14/05/2024 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Chief Executive Officer | 24/01/2023 |
Former positions of Aleksandra Rizo
| Companies | Position | End |
|---|---|---|
| GERON CORPORATION | Chief Tech/Sci/R&D Officer | 08/07/2022 |
| CELGENE | Corporate Officer/Principal | 01/01/2019 |
Janssen Research & Development LLC
 Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Corporate Officer/Principal | 01/03/2018 |
Training of Aleksandra Rizo
| Saints Cyril & Methodius University of Skopje | Doctorate Degree |
| University of Groningen | Doctorate Degree |
| University of Tokyo | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Janssen Research & Development LLC
Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Commercial Services |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Stock Market
- Insiders
- Aleksandra Rizo
